Quinn Sievers
@quinnsievers.bsky.social
Instructor in Lymphoma at Memorial Sloan Kettering and postdoc in the Abdel-Wahab and Vinogradova labs | Big problems, small molecules 🏳️🌈
Reposted by Quinn Sievers
Thrilled to share that the final piece of my PhD work is now on bioRxiv! biorxiv.org/content/10.1... With support from @nvidia and the @NSF, we used AlphaFold to screen 1.6M+ protein pairs, revealing thousands of potential novel PPIs. All data can be viewed at predictomes.org/hp
Proteome-wide in silico screening for human protein-protein interactions
Protein-protein interactions (PPIs) drive virtually all biological processes, yet most PPIs have not been identified and even more remain structurally unresolved. We developed a two-step computational...
biorxiv.org
November 12, 2025 at 9:26 PM
Thrilled to share that the final piece of my PhD work is now on bioRxiv! biorxiv.org/content/10.1... With support from @nvidia and the @NSF, we used AlphaFold to screen 1.6M+ protein pairs, revealing thousands of potential novel PPIs. All data can be viewed at predictomes.org/hp
Reposted by Quinn Sievers
Are you a postdoc in NYC? Come hang out with us at Postdoc Night Science! We are hosting the event at Columbia on Dec 3 at 5PM. Meet other NYC postdocs as well as @itaiyanai.bsky.social & @stearnslab.bsky.social to talk science & creativity! 🧬🧪
Make sure to use the QR code on the poster to sign up!
Make sure to use the QR code on the poster to sign up!
November 23, 2025 at 12:59 PM
Are you a postdoc in NYC? Come hang out with us at Postdoc Night Science! We are hosting the event at Columbia on Dec 3 at 5PM. Meet other NYC postdocs as well as @itaiyanai.bsky.social & @stearnslab.bsky.social to talk science & creativity! 🧬🧪
Make sure to use the QR code on the poster to sign up!
Make sure to use the QR code on the poster to sign up!
Reposted by Quinn Sievers
When I was interviewing for grad school (2011), the “missing heritability question” was THE burning question in genomics 1/
I wrote a little bit about the "missing heritability" question and several recent studies that have brought it to a close. A short 🧵
The missing heritability question is now (mostly) answered
Not with a bang but with a whimper
theinfinitesimal.substack.com
November 23, 2025 at 1:45 PM
When I was interviewing for grad school (2011), the “missing heritability question” was THE burning question in genomics 1/
Reposted by Quinn Sievers
Who doesn't love a library? A pooled library, that is! Grab a hot drink and your reading glasses and enjoy browsing the libraries Addgene has to offer:
https://twp.ai/4it3AO
https://twp.ai/4it3AO
November 19, 2025 at 3:00 PM
Who doesn't love a library? A pooled library, that is! Grab a hot drink and your reading glasses and enjoy browsing the libraries Addgene has to offer:
https://twp.ai/4it3AO
https://twp.ai/4it3AO
Reposted by Quinn Sievers
The Faculty of Arts and Sciences announced that it would reduce the number of Ph.D. admissions slots for the Science division by 50 percent this year, walking back plans for even steeper cuts.
William Mao and Veronica Paulus report.
www.thecrimson.com/article/2025...
William Mao and Veronica Paulus report.
www.thecrimson.com/article/2025...
Harvard To Admit 50% Fewer Ph.D. Students in Science, Walking Back Deeper Cuts | News | The Harvard Crimson
The Faculty of Arts and Sciences announced Wednesday that it would reduce the number of Ph.D. admissions slots for the Science division by 50 percent for the current admissions cycle, walking back…
www.thecrimson.com
November 19, 2025 at 5:17 PM
The Faculty of Arts and Sciences announced that it would reduce the number of Ph.D. admissions slots for the Science division by 50 percent this year, walking back plans for even steeper cuts.
William Mao and Veronica Paulus report.
www.thecrimson.com/article/2025...
William Mao and Veronica Paulus report.
www.thecrimson.com/article/2025...
Reposted by Quinn Sievers
Congratulations to Dr. Lorenzo Falchi of @mskcancercenter.bsky.social on the FDA approval of epcoritamab-bysp with lenalidomide and rituximab for adults with relapsed or refractory follicular #lymphoma! A huge win for those with the condition. Dr. Falchi will present phase 3 trial data at #ASH25.
The @fda.gov approved the immunotherapy epcoritamab-bysp with lenalidomide and rituximab for relapsed or refractory follicular lymphoma: buff.ly/JNJZKMb
FDA approves epcoritamab-bysp for follicular lymphoma indications
FDA approves epcoritamab-bysp for follicular lymphoma indications
www.fda.gov
November 18, 2025 at 7:14 PM
Congratulations to Dr. Lorenzo Falchi of @mskcancercenter.bsky.social on the FDA approval of epcoritamab-bysp with lenalidomide and rituximab for adults with relapsed or refractory follicular #lymphoma! A huge win for those with the condition. Dr. Falchi will present phase 3 trial data at #ASH25.
Reposted by Quinn Sievers
I envy the glycoscience community for their #glycotime hashtag. A great way to make posts visible. Anyone in #ChemicalProteomics that has a good idea, which hashtag we might use to make all of our work more visible and findable?
#ChemSky #ChemBio #DrugDiscovery #ABPP
www.nature.com/articles/s41...
#ChemSky #ChemBio #DrugDiscovery #ABPP
www.nature.com/articles/s41...
Probing the proteome - Nature Biotechnology
Chemical proteomics has brought rigor to covalent drug discovery and drugs to the clinic. Can it deliver a new generation of drug targets?
www.nature.com
November 18, 2025 at 11:03 AM
I envy the glycoscience community for their #glycotime hashtag. A great way to make posts visible. Anyone in #ChemicalProteomics that has a good idea, which hashtag we might use to make all of our work more visible and findable?
#ChemSky #ChemBio #DrugDiscovery #ABPP
www.nature.com/articles/s41...
#ChemSky #ChemBio #DrugDiscovery #ABPP
www.nature.com/articles/s41...
Reposted by Quinn Sievers
Ten days left to apply to be a @crick.ac.uk Early Career Group Leader
Closing date 27th November
www.crick.ac.uk/careers-stud...
Closing date 27th November
www.crick.ac.uk/careers-stud...
November 17, 2025 at 11:55 AM
Ten days left to apply to be a @crick.ac.uk Early Career Group Leader
Closing date 27th November
www.crick.ac.uk/careers-stud...
Closing date 27th November
www.crick.ac.uk/careers-stud...
Reposted by Quinn Sievers
An 89-year-old woman with severe tricuspid regurgitation presented with fever and cough after a recent diagnosis of influenza. Prominent forehead venous pulsations were noted on examination. Read the full case details: nej.md/3LtKUn3
#MedSky #CardioSky
#MedSky #CardioSky
November 17, 2025 at 8:01 PM
An 89-year-old woman with severe tricuspid regurgitation presented with fever and cough after a recent diagnosis of influenza. Prominent forehead venous pulsations were noted on examination. Read the full case details: nej.md/3LtKUn3
#MedSky #CardioSky
#MedSky #CardioSky
Reposted by Quinn Sievers
Orthogonal IMiD-Degron Pairs Induce Selective Protein Degradation in Cells
Orthogonal IMiD-Degron Pairs Induce Selective Protein Degradation in Cells
Immunomodulatory imide drugs (IMiDs), including thalidomide, lenalidomide, and pomalidomide, can be used to induce degradation of a protein of interest that is fused to a short degron motif, which oft...
pubs.acs.org
November 14, 2025 at 2:35 PM
Orthogonal IMiD-Degron Pairs Induce Selective Protein Degradation in Cells
Reposted by Quinn Sievers
Are there also folks looking for unmotivated, unenthusiastic postdocs or graduate students? Judging from how often I see these words in ads or postings, there must be some ads I am missing...
:)
:)
November 13, 2025 at 4:31 AM
Are there also folks looking for unmotivated, unenthusiastic postdocs or graduate students? Judging from how often I see these words in ads or postings, there must be some ads I am missing...
:)
:)
Reposted by Quinn Sievers
The Matthew Effect is alive and well in academia - always makes me wary of programs aimed at identifying rising stars in an already highly talented pool...
elifesciences.org/reviewed-pre...
elifesciences.org/reviewed-pre...
elifesciences.org
November 12, 2025 at 7:03 PM
The Matthew Effect is alive and well in academia - always makes me wary of programs aimed at identifying rising stars in an already highly talented pool...
elifesciences.org/reviewed-pre...
elifesciences.org/reviewed-pre...
Reposted by Quinn Sievers
In this manuscript, online today in Cancer Discovery, we investigate target-mediated resistance to ADCs, and propose ways to overcome it.
aacrjournals.org/cancerdiscov...
aacrjournals.org/cancerdiscov...
Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding
Abstract. T-DXd is clinically beneficial in HER2 positive and HER2 low metastatic breast cancer. However, therapeutic resistance emerges over time in most patients, with poorly defined resistance mech...
aacrjournals.org
November 10, 2025 at 4:55 PM
In this manuscript, online today in Cancer Discovery, we investigate target-mediated resistance to ADCs, and propose ways to overcome it.
aacrjournals.org/cancerdiscov...
aacrjournals.org/cancerdiscov...
Reposted by Quinn Sievers
Fred Hutch's Immunotherapy Integrated Research Center is recruiting an Open Rank Faculty position to lead a laboratory-based program focused on tumor immunology and cancer immunotherapy with a strong vision/path toward clinical translation.
Learn more: https://apply.interfolio.com/176403
Learn more: https://apply.interfolio.com/176403
November 12, 2025 at 1:13 AM
Fred Hutch's Immunotherapy Integrated Research Center is recruiting an Open Rank Faculty position to lead a laboratory-based program focused on tumor immunology and cancer immunotherapy with a strong vision/path toward clinical translation.
Learn more: https://apply.interfolio.com/176403
Learn more: https://apply.interfolio.com/176403
Reposted by Quinn Sievers
The FDA is reversing a 2003 decision that put a stringent warning on hormone therapy products for menopausal women, saying that the treatments offer heart, brain, and bone health benefits. www.statnews.com/2025/11/10/f...
FDA reverses decades-old warning on hormone therapy products for menopause
The FDA is reversing a 2003 decision that put a stringent warning on hormone therapy products for menopausal women, saying that the treatments offer heart, brain, and bone health benefits.
www.statnews.com
November 10, 2025 at 4:02 PM
The FDA is reversing a 2003 decision that put a stringent warning on hormone therapy products for menopausal women, saying that the treatments offer heart, brain, and bone health benefits. www.statnews.com/2025/11/10/f...
Reposted by Quinn Sievers
biology is so cool because like every week someone is like "Dr. Smith is coming to campus! She is the world expert in blargyblarg!"
And i'm like A) never heard of blargyblarg, B) look it up, it's super important and interesting
And i'm like A) never heard of blargyblarg, B) look it up, it's super important and interesting
November 4, 2025 at 7:24 PM
biology is so cool because like every week someone is like "Dr. Smith is coming to campus! She is the world expert in blargyblarg!"
And i'm like A) never heard of blargyblarg, B) look it up, it's super important and interesting
And i'm like A) never heard of blargyblarg, B) look it up, it's super important and interesting
Reposted by Quinn Sievers
OMG.
Arena BioWorks, an ambitious biomedical institute backed by billionaires, abruptly shuts down www.statnews.com/2025/11/04/a... via @statnews.com
Arena BioWorks, an ambitious biomedical institute backed by billionaires, abruptly shuts down www.statnews.com/2025/11/04/a... via @statnews.com
Arena BioWorks, an ambitious biomedical institute backed by billionaires, abruptly shuts down
Exclusive: Arena Bioworks, the buzzy research institute that launched with $500 million to support a decade of scientific R&D, is abruptly shutting down, STAT has learned.
www.statnews.com
November 5, 2025 at 1:40 AM
OMG.
Arena BioWorks, an ambitious biomedical institute backed by billionaires, abruptly shuts down www.statnews.com/2025/11/04/a... via @statnews.com
Arena BioWorks, an ambitious biomedical institute backed by billionaires, abruptly shuts down www.statnews.com/2025/11/04/a... via @statnews.com
Reposted by Quinn Sievers
Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm.
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
November 4, 2025 at 9:53 AM
Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm.
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Reposted by Quinn Sievers
A previously healthy man presented with a 10-day history of blood dripping from one nostril. Twenty days earlier, he had washed his face with mountain spring water. A leech was found on nasal endoscopy (shown in a video). Read the full case details: nej.md/3J6IZUD
#MedSky #Otolaryngology
#MedSky #Otolaryngology
November 3, 2025 at 8:16 PM
A previously healthy man presented with a 10-day history of blood dripping from one nostril. Twenty days earlier, he had washed his face with mountain spring water. A leech was found on nasal endoscopy (shown in a video). Read the full case details: nej.md/3J6IZUD
#MedSky #Otolaryngology
#MedSky #Otolaryngology